 | | Vol. 8.37 – 21 October, 2022 |
| |
|
|
| Using freshly resected primary colorectal cancer (CRC) tumors and patient-matched adjacent normal colon, scientists found divergent epigenetic landscapes between CRC tumors and cell lines.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers discovered that Zymosan-A upregulated the expression of ASCL2, promoted the regeneration of intestinal stem cells, and activated TLR2 and WNT signaling pathways, resulting in mitigated ionizing radiation-induced intestinal injury.
[Cell Death & Disease] |
|
|
|
| Investigators established intestinal organoids from tamoxifen-inducible intestinal epithelial cell-specific superoxide dismutase 1 (SOD1) knockout mice to explore the regulation of intestinal homeostasis.
[Cell Death & Disease] |
|
|
|
| Researchers reported the discovery and identification of several novel types of cyclic GMP-AMP synthase (cGAS) inhibitors by pyrophosphatase-coupled activity assays.
[Acta Pharmacologica Sinica] |
|
|
|
| Scientists investigated the effect of peoniflorin-6′-O-benzene sulfonate in the intestinal epithelial barrier and its mechanism.
[Phytotherapy Research] |
|
|
|
| Researchers evaluated the protective effect of Scheme B on cisplatin-induced rat intestinal crypt epithelial cell injury and the possible molecular mechanisms.
[Phytotherapy Research] |
|
|
|
| Scientists investigated the potential role of E3 ubiquitin-ligase Hakai in intestinal inflammation and cancer bowel disease and found increased expression in colon and gastric cancer compared to healthy colon tissues.
[Scientific Reports] |
|
|
|
|
| Investigators review the regulatory roles of miRNAs in the stability and maintenance of the gut immune–microbiome axis and detail the challenges and recent advances in using miRNAs as putative therapeutic agents for treating inflammatory bowel disease.
[Trends in Immunology] |
|
|
|
|
| Erasca, Inc. announced a clinical trial collaboration and supply agreement with Pfizer Inc. for the CDK4/6 inhibitor palbociclib.
[Erasca, Inc.] |
|
|
|
| XBiotech announced the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer.
[XBiotech USA, Inc.] |
|
|
|
|
| November 14 – 17, 2022
Portland, Oregon, United States |
|
|
|
|
|
| | Duke University – Durham, North Carolina, United States |
|
|
|
| | AstraZeneca – Gaithersburg, Maryland, United States |
|
|
|
| | University of Southern Denmark – Odense, Denmark |
|
|
|
| | Brigham and Women’s Hospital – Boston, Massachusetts, United States |
|
|
|
| | University of Colorado Denver – Aurora, Colorado, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
